Recursion to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Recursion (RXRX) to participate in key investor conferences in March 2024, showcasing its innovative TechBio approach to drug discovery.

SALT LAKE CITY, March 01, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conferences:

• Morgan Stanley Technology, Media and Telecom Conference – March 4-7, 2024
• KeyBanc Emerging Technology Summit – March 5-6, 2024
• Leerink Partners Global Biopharma Conference – March 11-13, 2024
• KeyBanc Life Sciences & MedTech Investor Forum – March 19-20, 2024

About Recursion

Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine. 

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Forward-Looking Statements

This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding early and late stage discovery, preclinical, and clinical programs; licenses and collaborations; prospective products and their potential future indications and market opportunities; Recursion OS and other technologies; business and financial plans and performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as “plan,” “will,” “expect,” “anticipate,” “intend,” “believe,” “potential,” “continue,” and similar terms. These statements are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements, including but not limited to: challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure is high and failure can occur at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to leverage and enhance our drug discovery platform; our ability to obtain financing for development activities and other corporate purposes; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; our ability to obtain, maintain, and enforce intellectual property protections; cyberattacks or other disruptions to our technology systems; our ability to attract, motivate, and retain key employees and manage our growth; inflation and other macroeconomic issues; and other risks and uncertainties such as those described under the heading “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K. All forward-looking statements are based on management’s current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.

When will Recursion participate in the Morgan Stanley Technology, Media and Telecom Conference?

Recursion will participate in the Morgan Stanley Technology, Media and Telecom Conference from March 4-7, 2024.

Which investor conference will Recursion attend on March 5-6, 2024?

Recursion will attend the KeyBanc Emerging Technology Summit on March 5-6, 2024.

What is the focus of Recursion at the Leerink Partners Global Biopharma Conference from March 11-13, 2024?

Recursion will focus on its global biopharma initiatives at the Leerink Partners Global Biopharma Conference from March 11-13, 2024.

Which conference will Recursion be a part of on March 19-20, 2024?

Recursion will be part of the KeyBanc Life Sciences & MedTech Investor Forum on March 19-20, 2024.